IPC alert: About Norfloxacin induced skin hyperpigmentation

Norfloxacin is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics.

The Health Master

December 8, 2022

560

Last Updated on October 10, 2024 by The Health Master

The Indian Pharmacopoeia Commission (IPC), which is the National Coordination Centre (NCC) for the Pharmacovigilance Programme of India (PvPI), has flagged a drug safety alert revealing that antibacterial norfloxacin is associated with an adverse event known as skin hyperpigmentation.

This came to light after the preliminary analysis of adverse drug reactions (ADRs) in the PvPI database.

Follow us on WhtasApp Channel

Norfloxacin is used to treat a variety of bacterial infections. This medication belongs to a class of drugs known as quinolone antibiotics.

It is indicated in the treatment of acute uncomplicated/complicated chronic, recurrent urinary tract infections, including pyelonephritis, urethritis and gonococcal infections.

Click for more articles on IPC

It is also indicated in a wide variety of infections caused by susceptible gram-positive and gram-negative organisms including mixed infection in poultry.

Norfloxacin’s mode of action depends on blocking bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably, the drug has a 100 times higher affinity for bacterial DNA gyrase than for mammals.

As per the drug safety alert issued by IPC last week of November, norfloxacin is linked with skin hyperpigmentation.

Hyperpigmentation refers to patches of skin that become darker than the surrounding areas of skin. It occurs when the skin produces excess melanin, the pigment that gives skin its colour.

Click for more on Norfloxacin

Healthcare professionals and patients have been advised to closely monitor the possibility of the above ADR associated with the use of norfloxacin.

If such a reaction is encountered, it needs to be reported to the NCC-PvPI for suitable action.

Earlier, IPC had also flagged drug safety alerts revealing that amoxicillin, a penicillin-type antibiotic, was associated with an adverse event known as a “fixed drug eruption.”

Besides this, nonsteroidal anti-inflammatory drugs (NSAID), piroxicam; beta-lactam antimicrobials, cephalosporins and anti-inflammatory drug, ibuprofen were also found to be associated with adverse events known as fixed drug eruption.

Click for more articles on CDSCO

Furthermore, IPC also cautioned that the second-generation cephalosporin antibiotic, cefuroxime, was associated with drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, while the immunosuppressive medicine tacrolimus was linked with an adverse event known as gingival hypertrophy.

It further revealed that the antifungal medicine itraconazole caused an adverse event known as Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE).

PvPI was implemented by the CDSCO in July 2010 across the country.

Since then, IPC has been mandated to establish clinical evidence between the drug and the ADR event through a robust system of causality assessment.